Revolution Medicines (RVMD) priced a public offering of 10.56M shares at $142 each, raising about $1.5B, along with $500M of convertible senior notes due 2033. Both offerings were upsized from earlier ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the ...
On August 12, 2025, the Board approved a reverse stock split of the Company’s outstanding shares of Common Stock at a ratio of one-for-five (the “Reverse Stock Split”). The Reverse Stock Split is ...
8d
Tamboran Resources Corporation Registered Direct Institutional Entitlement Offering of Common Stock
Tamboran Resources has commenced a registered direct institutional entitlement offer of Common Stock pursuant to an effective registration statement filed with the Securities and Exchange Commission ...
New York City-based National Healthcare Properties has publicly filed a registration statement with the Securities and Exchange Commission proposing a public offering of its Class A common stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results